Clinical Trial Update: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated two ribociclib dose levels in combination with aromatase inhibitors for HR-positive, HER2-negative advanced breast cancer; the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Kisqali (ribociclib) (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-04-05